Complete ELEVECTA™ Cell Line Portfolio For AAV Manufacturing
Optimize your cell line strategy for better viral vector production.
The HEK293-based ELEVECTA™ cell line portfolio combines innovative design and deep expertise to deliver transient, packaging, and producer options that provide competitive performance, high quality, and flexibility for your viral vector production.
ELEVECTA™ transient cell line
Preserves flexibility while delivering excellent performance and quality - all aimed at quickly advancing candidates to clinical trials.
ELEVECTA™ packaging cell line
Contains all genes except the transgene; allows streamlining the screening of assets that use the same capsid to target the same tissue type.
ELEVECTA™ producer cell line
Contains all genes to produce AAV; simply induce. The result is a simplified, robust, upstream process that easily scales to treat hundreds of thousands.